Clinical Trials Browser

Phase 1/2 × Unknown × Triple Negative Breast Neoplasms × Clear all

NCT05928780 2023-07-03

An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC in First-line Treatment (FUTURE-Trop2)

Phase 1/2 Unknown

Triple Negative Breast Neoplasms

NCT05746728 2023-04-06

Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Cancer

Phase 1/2 Unknown

Triple Negative Breast Neoplasms

NCT03475953 2023-03-03

REGOMUNE

Phase 1/2 Unknown

BreastEndocrineGastrointestinalGenitourinaryHead & NeckNETOther solid neoplasmSarcomaThoracic

Gastro-enteropancreatic neuroendocrine tumor, Turcot syndrome, Tertiary Lymphoid Structures, Mesothelioma, Malignant, Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Neoplasm Metastasis, Sarcoma, Stomach Neoplasms, Thyroid Neoplasms, Triple Negative Breast Neoplasms

NCT03805399 2022-08-10

FUTURE

Phase 1/2 Unknown

Triple Negative Breast Neoplasms

NCT04609215 2022-04-20

ImmunoBreast - A Phase Ib Study

Phase 1/2 Unknown

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05103917 2021-11-02

A Study to Assess the Safety, Tolerability and Antitumor Activity of X4P-001 in Combination With TNBC

Phase 1/2 Unknown

Triple Negative Breast Neoplasms

NCT04750382 2021-02-11

A Study of HX008 for the Treatment of Patients With Metastatic Triple Negative Breast Cancer

Phase 1/2 Unknown

Triple Negative Breast Neoplasms

NCT02583542 2020-02-25

TORCMEK

Phase 1/2 Unknown

Triple Negative Breast Neoplasms

NCT04213898 2019-12-30

SHR-1210 Combined With Albumin-bound Paclitaxel and Epirubicin Neoadjuvant for Triple Negative Breast Cancer

Phase 1/2 Unknown

Triple Negative Breast Neoplasms